# SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial

> **NCT07748611** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Northwestern University** · enrollment: 125 (estimated)

## Conditions studied

- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Resectable Pancreatic Ductal Adenocarcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **OTHER:** Electronic Health Record Review
- **DRUG:** Fluorouracil
- **DRUG:** Gemcitabine
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Nab-paclitaxel
- **DRUG:** Oxaliplatin
- **RADIATION:** Radiation Therapy
- **PROCEDURE:** Surgical Procedure

## Key facts

- **NCT ID:** NCT07748611
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-02-03
- **Primary completion:** 2030-02-03
- **Final completion:** 2031-02-03
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2026-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07748611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07748611, "SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07748611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*